The ACC created the Managing AFib and BTK Inhibitors: Balancing Risk online course to educate the medical community about the importance of assessing risk, monitoring, and managing AFib and other cardiovascular risk factors for oncology patients. Review important topics such as patient-specific risk factors, antiplatelet activity of Bruton's tyrosine kinase (BTK) inhibitors and drug-drug interactions, as well as the steps to anticoagulation and dosing requirements in different CLL patients with this interactive infographic – Anticoagulation for AFib in Patients Receiving BTK Inhibitors. Stay up to date on best practices to guide clinical decision making and improve management of patients and more. Learn more.